We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Test Helps Diagnose Inaccessible Brain Tumors

By LabMedica International staff writers
Posted on 03 Jan 2023

Worldwide, brain cancer is the 12th most lethal cancer, and each year, more than 250,000 adults die due to the disease. More...

Diagnosis of brain tumors is resource-intensive, risk-prone and brain biopsies are impossible to perform in almost 40% of advanced cases. Presently, no blood test is available for diagnosing brain cancers, and doctors have to rely on complex surgical procedures to obtain tumor tissue for histopathological evaluation. Now, a new blood test can detect the cells released from the brain tumor that are extremely rare and hard to detect, enabling early diagnosis and treatment.

The TriNetra-Glio liquid biopsy from Datar Cancer Genetics Inc. (London, UK) is a blood test to help in the diagnosis of brain tumors where a conventional biopsy is not possible. The test requires only a blood draw and can help detect brain tumors in asymptomatic adult males and females based on the presence of Circulating Tumor Cells (CTCs). The test evaluates blood samples for the presence of CTCs which may be further analyzed to determine the organ or tissue of origin. The TriNetra-Glio liquid biopsy requires 15 ml blood and is indicated for patients where a brain biopsy, although necessary, cannot be performed or has been unsuccessful. In a prospective, blinded study, the test has shown very high accuracy in detecting malignant brain tumors. The TriNetra-Glio liquid biopsy has received Breakthrough Device Designation from the US FDA after previously receiving CE certification and is already available to patients as Trublood-CNS.

"The breakthrough designation is a recognition of the potential benefits of TriNetra-Glio in the clinical setting. The test can help individuals where a brain biopsy or surgical resection of the tumor is not possible due to the location of the tumor or other constraints. With our proprietary CTC-enrichment and detection technology, a diagnosis of inaccessible tumors will become possible through a risk-free and patient-friendly blood test," said Dr. Vineet Datta, Executive Director of the company.

Related Links:
Datar Cancer Genetics Inc.


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mumps Test
ReQuest MUMPS IgM Assay
New
Chlamydia Pneumoniae Test
Chlamydia Pneumoniae (CP) Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: This image shows a second-generation version of the device that can also measure cell morphology (Photo courtesy of MIT)

Rapid Cell Density Measurement Technique to Help Predict Immunotherapy Response

The density of a cell provides valuable insights into its condition. As cells go through processes such as proliferation, differentiation, or cell death, they may gain or lose water and other molecules,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.